The endocannabinoid system in local and systemic inflammation / Melanie E. M. Kelly, Christian Lehmann, Juan Zhou.

Format:

Book

Author/Creator:

Kelly, Melanie E. M., author.

Zhou, Juan, author.

Lehmann, Christian (Professor of anesthesia), author.

Series:

Colloquium series on integrated systems physiology ; # 74.

Colloquium digital library of life sciences

Colloquium series on integrated systems physiology ; 74

Language:

English

Subjects (All):

Inflammation--Mediators.

Inflammation.

Cannabinoids--Therapeutic use.

Cannabinoids.

Inflammation--therapy.

Inflammation Mediators.

Cannabinoids--therapeutic use.

Inflammation--Treatment.

Medical Subjects:

Inflammation--therapy.

Inflammation Mediators.

Cannabinoids--therapeutic use.

Physical Description:

1 online resource (xii, 195 pages) : illustrations.

Place of Publication:

[San Rafael, California] : Morgan & Claypool, 2017.

System Details:

System requirements: Adobe Acrobat reader.

Mode of access: World Wide Web.

text file

Summary:

This book focuses on the role of the endocannabinoid system in local and systemic inflammation, with individual chapters written by experts in the field of cannabinoid research and medicine. The topics explore the actions of the endocannabinoid system on the immune system, including neuroinflammation in autoimmune disorders such as multiple sclerosis, and in neurodegenerative disorders such as Huntington's and Alzheimer's, as well as local and systemic inflammatory conditions affecting organs including the eye (uveitis and corneal inflammation), the bladder (interstitial cystitis), pancreas (diabetes), cardiovascular system (stroke), joints (arthritis), and sepsis. The objective of this book is to provide knowledge transfer on the use of cannabinoids in inflammatory disease by critically examining preclinical and clinical research on the immunomodulatory actions of the endocannabinoid system, with specific emphasis on the actions of cannabinoids in diseases where inflammation is a prominent component. By drawing these results together, we seek to provide further understanding of the complexities of endocannabinoid system modulation of immune function and identify potential uses and limitations for cannabinoid-based therapeutics.

Contents:

Lead author biographies

Contributing author biographies

References.

10. Immune modulation by cannabinoids during central nervous system injury-induced neuroinflammation

10.1 Central nervous system injury

10.2 The endocannabinoid system

10.3 The endocannabinoid system, central nervous system injury and inflammation

10.4 Endocannabinoid therapies for central nervous system injury

10.5 Targeting cannabinoid receptors for central nervous system injury

10.6 Conclusion

9. Cannabinoid 2 receptor activation in sepsis

9.1 Introduction

9.2 Cannabinoid 2 receptor, an immunosuppressive target in sepsis

9.3 Cannabinoid type 2 receptor signaling in sepsis

9.4 Cannabinoid 2 receptor and sepsis survival

9.5 Other endocannabinoid system targets in sepsis

9.5.1 CB1R

9.5.2 GPR55

9.6 Conclusion

8. Arthritis and the endocannabinoid system

8.1 Introduction to arthritis

8.2 Common types of arthritis

8.2.1 Osteoarthritis

8.2.2 Rheumatoid arthritis

8.2.3 Gout

8.3 Overview of cannabinoids

8.3.1 Localization of the endocannabinoid system in joints

8.3.2 Effects of endocannabinoids on arthritis pathology

8.3.3 Effect of endocannabinoids on joint pain

8.3.4 Effect of endocannabinoids on inflammation

8.3.5 Effect of endocannabinoids on neuropathic pain

8.4 On considering a variety of therapeutic implications for cannabinoids

8.5 Conclusion

7. Role of the endocannabinoid system in interstitial cystitis

7.1 Introduction

7.2 Interstitial cystitis

7.3 Physiology and pathophysiology of interstitial cystitis

7.4 The endocannabinoid system

7.5 The endocannabinoid system in experimental interstitial cystitis

7.6 Cannabinoid 1 receptor and bladder pathophysiology

7.7 Cannabinoid 2 receptor and bladder pathophysiology

7.8 The endocannabinoid system and cannabinoids in cystitis patients

7.9 Conclusion

5. The endocannabinoid system's role in ocular inflammation

5.1 The endocannabinoid system and marijuana

5.2 Endocannabinoid system in ocular tissue

5.3 The ocular inflammatory response and the endocannabinoid system

5.4 Diseases associated with ocular inflammation

5.4.1 Uveitis

5.4.2 Proliferative vitreoretinopathy

5.4.3 Diabetic retinopathy

5.5 Conclusion

4. Alzheimer's, neuroinflammation and the endocannabinoid system

4.1 Introduction to Alzheimer's disease

4.2 Alzheimer's disease treatments and the endocannabinoid system

4.3 Cannabinoid receptors

4.4 Neuroinflammation in Alzheimer's disease

4.5 Microglia in Alzheimer's disease

4.6 Hippocampal long-term potentiation in models of Alzheimer's disease

4.7 Cannabinoid receptors as a therapeutic target in Alzheimer's disease

4.7.1 Anandamide

4.7.2 Tetrahydrocannabinol and cannabidiol

4.8 Cannabinoids and the blood brain-barrier in Alzheimer's disease: hemi-channels and astrocytes

4.9 Therapeutic implications for cannabinoids

3. Huntington's disease and the endocannabinoid system

3.1 Huntington's disease

3.2 Neuroinflammation in Huntington's disease

3.3 The management of neuroinflammation in Huntington's disease

3.4 Endocannabinoid system in Huntington's disease

3.5 Modulation of the endocannabinoidal system to minimize neuroinflammation and neurodegeneration in Huntington's disease

2. Cannabinoids in multiple sclerosis

2.1 Multiple sclerosis

2.1.1 Etiology

2.1.2 Pathology and symptoms of multiple sclerosis

2.1.3 Current treatments for multiple sclerosis

2.2 Cannabinoids in multiple sclerosis

2.2.1 Experimental autoimmune encephalomyelitis animal models

2.2.2 Clinical data

2.2.3 Tolerability of cannabinoids

2.3 Concluding remarks and future directions

1. Inflammation and the endocannabinoid system

1.1 Introduction

1.2 Cannabinoid type 1 receptor

1.3 Cannabinoid type 2 receptor

1.4 Other receptors and ligands

1.5 Modulation of the inflammatory immune response by the endocannabinoid system

1.6 Conclusions

6. Cannabidiol as a potential clinical therapeutic agent for the reduction of pancreatic inflammation in early type 1 diabetes mellitus

6.1 Introduction

6.2 Pathogenesis of type 1 diabetes

6.3 Current therapies

6.4 Cannabidiol pharmacology

6.5 Cannabidiol for prophylaxis of type 1 diabetes

6.6 Conclusion

Notes:

Part of: Colloquium digital library of life sciences.

Includes bibliographical references (pages 115-195).

Title from PDF title page (viewed on February 24, 2017).

Other Format:

Print version:

ISBN:

9781615047499

OCLC:

982701697

Access Restriction:

Restricted for use by site license.